Back to today’s briefing

Story perspectives

GLP-1 Agonists Slash Heart Failure Risks by 58%

8/31/2025

25 4

Summary

Story summary

A study shows GLP-1 agonists, such as semaglutide and tirzepatide, can lower hospitalization or death risk in heart failure patients by 58%.
The research involved over 90,000 patients, suggesting benefits beyond weight loss.
Experts call for further evidence before broad clinical use.
Findings were shared at the European Society of Cardiology conference and published in JAMA.

1 of 1

Story summary

A study shows GLP-1 agonists, such as semaglutide and tirzepatide, can lower hospitalization or death risk in heart failure patients by 58%.
The research involved over 90,000 patients, suggesting benefits beyond weight loss.
Experts call for further evidence before broad clinical use.
Findings were shared at the European Society of Cardiology conference and published in JAMA.